How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/simvastatin-lovaza.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Simvastatin + Lovaza — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Simvastatin + Lovaza (Simvastatin + Lovaza) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statin + Omega-3 fatty acid combination. Area: Cardiovascular.

phase 3 Statin + Omega-3 fatty acid combination HMG-CoA reductase (simvastatin); VLDL synthesis and triglyceride metabolism (Lovaza) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Simvastatin + Lovaza (Simvastatin + Lovaza) — GlaxoSmithKline. Simvastatin lowers LDL cholesterol by inhibiting HMG-CoA reductase, while Lovaza (omega-3 fatty acids) reduces triglycerides through multiple pathways including reduced hepatic VLDL production.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Simvastatin + Lovaza TARGET	Simvastatin + Lovaza	GlaxoSmithKline	phase 3	Statin + Omega-3 fatty acid combination	HMG-CoA reductase (simvastatin); VLDL synthesis and triglyceride metabolism (Lovaza)
Omega 3-Atorvastatin	Omega 3-Atorvastatin	Seoul National University Bundang Hospital	marketed	Statin + omega-3 fatty acid combination	HMG-CoA reductase (atorvastatin); GPR120, GPR40 (omega-3 signaling)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Statin + Omega-3 fatty acid combination class)

GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Simvastatin + Lovaza — Competitive Intelligence Brief. https://druglandscape.com/ci/simvastatin-lovaza. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing